Adenosine mechanisms are not affected by antidepressant concentrations of desipramine

Area of Science:

• Neuropharmacology
• Biochemistry

Background:

• Adenosine is a neuromodulator implicated in various physiological processes.
• Tricyclic antidepressants (TCAs) are widely used for treating depression.
• The potential role of adenosine in TCA action remains unclear.

Purpose of the Study:

• To investigate whether adenosine mediates the effects of tricyclic antidepressant therapy.
• To examine the impact of desipramine on adenosine-mediated signaling pathways in the hippocampus.

Main Methods:

• In vitro experiments using hippocampal slices to assess adenosine-stimulated cyclic AMP (cAMP) formation.
• Evaluation of ATP, ADP, and AMP levels, and purine release.
• In vivo studies involving long-term antidepressant treatment followed by in vitro receptor sensitivity assays.

Main Results:

• Desipramine (DMI) did not affect adenosine-induced inhibition of lipolysis or cAMP formation at therapeutic concentrations.
• Very high DMI concentrations potentiated adenosine's effect on cAMP formation.
• Long-term TCA treatment did not alter adenosine receptor sensitivity but depressed beta-adrenoceptor-mediated cAMP formation.

Conclusions:

• Central adenosine mechanisms are unlikely to be involved in the therapeutic effects of tricyclic antidepressants.
• The study suggests that TCAs' primary actions do not involve significant modulation of adenosine signaling pathways.